Krezsita 50 Tablet contains Sitagliptin 50 mg, a selective dipeptidyl peptidase-4 (DPP-4) inhibitor indicated for the management of type 2 diabetes mellitus. Sitagliptin enhances the body's ability to regulate blood glucose by increasing the levels of incretin hormones, which stimulate insulin release from pancreatic beta cells and suppress glucagon secretion from alpha cells in a glucose-dependent manner. This mechanism helps improve glycemic control without causing significant hypoglycemia. Krezsita 50 is typically prescribed as monotherapy or in combination with other antidiabetic agents such as metformin, sulfonylureas, or insulin when diet and exercise alone do not provide adequate glycemic control. It is administered orally, once daily, with or without food. The medication is generally well tolerated; common adverse effects may include nasopharyngitis, headache, and upper respiratory tract infections. Caution is advised in patients with renal impairment, and dose adjustments may be necessary. Krezsita 50 should be used under medical supervision, with regular monitoring of blood glucose levels and renal function to optimize therapeutic outcomes and minimize potential risks. It is not indicated for type 1 diabetes or diabetic ketoacidosis.

Dosage & How to Use